Autoimmune diseases are among the most common diseases in America, affecting more than 23.5 million people1. It is an illness that causes the immune system to produce antibodies that attack the normal body tissue.2 Glenmark is exploring new, potential first- and best-in-class treatments for serious autoimmune diseases.

Glenmark’s most advanced immunology candidate, GBR 830, is an investigational treatment intended for patients with moderate-to-severe atopic dermatitis (AD). AD is an autoimmune disorder and is the most common inflammatory skin disease, affecting up to 3% of the adult population globally, and its prevalence has increased 2-3 fold over the last decades3. Recent advances in the understanding and treatment of moderate-to-severe AD have included identification of molecules in the human immune system that activate the disease. GBR 830 is a first-in-class, monoclonal antibody designed to inhibit OX40, a costimulatory immune checkpoint receptor expressed on activated T cells and memory T cells. Costimulatory signals are essential for T cell activity, and binding between OX40 and OX40L is a biomarker for the severity of autoimmune diseases. The pathway leads to conversion of activated T cells into memory T cells, which promotes inflammation. In addition, regulatory T cells also contribute to inflammation, and OX40 signaling by these cells downregulates immune-suppressing functions. It is believed that GBR 830 inhibits the dual activities of OX40 and OX40L binding in both activated T cells and regulatory T cells, thus reducing inflammation associated with symptoms of AD.

Click here to view our innovative pipeline.


AD is the most common inflammatory skin disease, affecting more than 31 million Americans including
10%–30% of children under the age of 18

For more information about patient resources, please visit:
American Academy of Allergy, Asthma & Immunology. , accessed August 1, 2019, accessed August 1, 2019

3 Ann Nutr Metab 2015;66(suppl 1):8-16 accessed August 1, 2019